07 Nov CVCT-CardioVascular Clinical Trialists Washington DC 30 Nov-2 Dec
CellProthera will participate in the Global CardioVascular Clinical Trialists Forum (CVCT) on November 30 - December 2nd,...
Author: equipe
04 Oct University Hospitals Birmingham Connected: Heart patient given new lease of life
Kim Smith, a 66-year-old heart attack patient, experienced a life-changing breaktrough after receiving stem cell therapy at Queen Elizabeth Hospital Birmingham (QEHB)
26 Sep PHARMIWEB: CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy
Final patient receives ProtheraCytes(R) cell therapy to regenerate damaged heart tissue following severe heart attack. Study remains on track for final readout in H1 2024
26 Sep CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy
- Final patient receives ProtheraCytes® cell therapy to regenerate damaged heart tissue following severe heart attack
- Study remains on track for final readout in H1 2024
31 Jul DDW – Turning science into business: Can regenerative medicine treat heart attacks?
DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.
28 Jul ITV News Central: Innovative stem cell therapy offers heart attack patient a new lease of life
ITV News Central | Marc Goug 28 July 2023...
30 Jun MED-TECH INNOVATION | NEWS: Trans-endocardial delivery: The importance of the right solution
Peter Altman, CEO of BioCardia, and Matthieu de Kalbermatten, CEO of CellProthera, comment on trans-endocardial intramyocardial delivery systems for biotherapeutics to treat heart failure, ischemia, and infarction, and the importance of the right delivery solution.
09 Jun EPR : Regenerative potential – cell-based therapies for heart failure
"Cell-based therapies have the potential to regenerate heart tissue as an alternative to heart transplante. Here, Dr Ibon GARITAONANDIA, Chief Scientific Officer at CellProthera, shares how CD34+ cells are demonstrating promising results in clinical studies."
17 Apr Genetic Engineering & Biotechnology News : Tech advances will help cell therapy makers cope with variable starting materials
"Autologous cell therapies are made from living cells, harvested from specific people. Every batch of inputs is different which makes predicting how each will perform in manufacturing a major challenge.Indeed, for Matthieu de Kalbermatten, CEO of France-based cell therapy developer CellProthera, starting material variability is the major issue facing the industry."
03 Apr Biotechgate – BioCardia and CellProthera Enhance Collaboration
" BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients"